Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00519662 | Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors | PHASE1 | COMPLETED | 32 | — | — | Aug 1, 2007 | Mar 1, 2009 | Apr 4, 2017 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| Dose escalating cohorts of SNS-314 | EXPERIMENTAL | Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema. |
| Name | Type | Description |
|---|---|---|
| SNS-314 | DRUG | Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15 Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1 |
Inclusion Criteria: * Advanced solid tumor and that is measurable by a scan Exclusion Criteria: * Uncontrolled or untreated central nervous system metastases * Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day 1 * Any of the following cardiac conditions: * Histo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |